{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T20:30:30Z","timestamp":1778358630294,"version":"3.51.4"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1097\/jcma.0000000000000062","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T11:52:11Z","timestamp":1553169131000},"page":"265-271","source":"Crossref","is-referenced-by-count":8,"title":["A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab"],"prefix":"10.1097","volume":"82","author":[{"given":"Ting-Hsing","family":"Chao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pi-Jung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-En","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Jen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Tien","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhih-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-I","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsong-Hai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210129","doi-asserted-by":"crossref","first-page":"e001066","DOI":"10.1161\/JAHA.114.001066","article-title":"Trends in the incidence and management of acute myocardial infarction from 1999 to 2008: get with the guidelines performance measures in Taiwan.","volume":"3","author":"Lee","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"R2-5-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijcard.2016.02.022","article-title":"The temporal trends of incidence, treatment, and in-hospital mortality of acute myocardial infarction over 15 years in a Taiwanese population.","volume":"209","author":"Yin","year":"2016","journal-title":"Int J Cardiol"},{"key":"R4-5-20210129","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R5-5-20210129","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study.","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"R6-5-20210129","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias.","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"R8-5-20210129","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-5-20210129","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jfma.2013.10.007","article-title":"Guideline-adherent therapy in patients with cardiovascular diseases in Taiwan.","volume":"114","author":"Jeng","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"R10-5-20210129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/1741826710397100","article-title":"Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.","volume":"19","author":"Park","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"R11-5-20210129","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcma.2013.10.013","article-title":"Determinants of low-density lipoprotein cholesterol goal attainment: insights from the CEPHEUS Pan-Asian Survey.","volume":"77","author":"Wang","year":"2014","journal-title":"J Chin Med Assoc"},{"key":"R12-5-20210129","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1185\/03007990802138731","article-title":"Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study.","volume":"24","author":"Kim","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R13-5-20210129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOL.0000000000000295","article-title":"New developments in proprotein convertase subtilisin-kexin 9\u2019s biology and clinical implications.","volume":"27","author":"Seidah","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"R14-5-20210129","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on expert consensus decision pathways.","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R15-5-20210129","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"R16-5-20210129","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study.","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"R17-5-20210129","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R18-5-20210129","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"R19-5-20210129","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins-ODYSSEY JAPAN randomized controlled trial.","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"key":"R20-5-20210129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacl.2017.09.007","article-title":"A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT","volume":"12","author":"Koh","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R21-5-20210129","first-page":"217","article-title":"Racial differences in response to antihypertensive therapy: does one size fits all?","volume":"1","author":"Gupta","year":"2010","journal-title":"Int J Prev Med"},{"key":"R22-5-20210129","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2133\/dmpk.DMPK-10-RG-112","article-title":"Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.","volume":"26","author":"Oishi","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"R23-5-20210129","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcma.2016.02.010","article-title":"Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study.","volume":"79","author":"Chen","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"R24-5-20210129","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1160\/TH13-11-0948","article-title":"Stroke prevention in atrial fibrillation: an Asian perspective.","volume":"111","author":"Chiang","year":"2014","journal-title":"Thromb Haemost"},{"key":"R25-5-20210129","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R26-5-20210129","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.5551\/jat.24158","article-title":"The association between low-density lipoprotein cholesterol goal attainment, physicians and patients attitudes and perceptions, and healthcare policy.","volume":"21","author":"Wang","year":"2014","journal-title":"J Atheroscler and Thromb"},{"key":"R27-5-20210129","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.jacc.2015.06.1356","article-title":"Treatment of dyslipidemia in elderly patients with coronary heart disease: there are miles to go before we sleep.","volume":"66","author":"Toth","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R28-5-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1475-2840-9-24","article-title":"\u201cIf it ain\u2019t broke, don\u2019t fix it\u201d: a commentary on the positive-negative results of the ACCORD Lipid study.","volume":"9","author":"Tenenbaum","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"R29-5-20210129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.amjcard.2017.06.023","article-title":"Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II).","volume":"120","author":"El Shahawy","year":"2017","journal-title":"Am J Cardiol"},{"key":"R30-5-20210129","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial.","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-5-20210129","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11886-017-0882-6","article-title":"PCSK9 inhibitors: treating the right patients in daily practice.","volume":"19","author":"King","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"R32-5-20210129","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ecl.2014.08.008","article-title":"New therapies for reducing low-density lipoprotein cholesterol.","volume":"43","author":"Stein","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R33-5-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5551\/jat.RV16004","article-title":"Racial differences in the cholesterol-lowering effect of statin.","volume":"24","author":"Naito","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"R34-5-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R35-5-20210129","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: mechanism of action and effects.","volume":"5","author":"Stancu","year":"2001","journal-title":"J Cell Mol Med"},{"key":"R36-5-20210129","doi-asserted-by":"crossref","first-page":"e006910","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials.","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R37-5-20210129","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial.","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"R38-5-20210129","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"R39-5-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/0975-7406.171699","article-title":"Statins and its hepatic effects: newer data, implications, and changing recommendations.","volume":"8","author":"Jose","year":"2016","journal-title":"J Pharm Bioallied Sci"},{"key":"R40-5-20210129","first-page":"605","article-title":"Statins and liver injury.","volume":"9","author":"Thapar","year":"2013","journal-title":"Gastroenterol Hepatol (N Y"},{"key":"R41-5-20210129","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab.","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"R42-5-20210129","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R43-5-20210129","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 Inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R44-5-20210129","doi-asserted-by":"crossref","first-page":"e003497","DOI":"10.1161\/JAHA.116.003497","article-title":"Plasma levels of proprotein convertase subtilisin\/kexin type 9 are elevated in patients with peripheral artery disease and associated with metabolic disorders and dysfunction in circulating progenitor cells.","volume":"5","author":"Chao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R45-5-20210129","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"R46-5-20210129","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Journal of the Chinese Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCMA.0000000000000062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:34:05Z","timestamp":1620956045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02118582-201904000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/jcma.0000000000000062","relation":{},"ISSN":["1726-4901"],"issn-type":[{"value":"1726-4901","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}